NPSP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
NPSP' s Interest Coverage Range Over the Past 10 Years
Min: 0 Med: 0.00 Max: 0
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
|Eric Mindich 408,141 sh (New)|
Louis Moore Bacon 25,000 sh (New)
Joel Greenblatt 12,104 sh (New)
Mariko Gordon 15,986 sh (+7.81%)
|Louis Moore Bacon 30,000 sh (unchged)||John Burbank Sold Out|
Jim Simons Sold Out
RS Investment Management Sold Out
Pioneer Investments 253,897 sh (-7.42%)
Columbia Wanger 1,736,720 sh (-37.33%)
|Paul Tudor Jones 8,388 sh (New)|
Mariko Gordon 16,864 sh (+5.49%)
|Pioneer Investments 418,971 sh (unchged)||Louis Moore Bacon Sold Out|
Eric Mindich Sold Out
Joel Greenblatt Sold Out
Columbia Wanger 1,257,320 sh (-27.60%)
|Ken Fisher 9,350 sh (New)|
Joel Greenblatt 5,743 sh (New)
Pioneer Investments 524,878 sh (+25.28%)
Paul Tudor Jones 10,016 sh (+19.41%)
|Mariko Gordon Sold Out|
Columbia Wanger 1,217,320 sh (-3.18%)
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
|Short Percentage of Float||5.50%|
|52-Week Range $||22.11 - 46.01|
|EPS without NRI($)||0.01||1.06||2.17||2.76|
|Industry:||Biotechnology » Biotechnology|
|Compare:||XSWX:ROG, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details|
|Traded in other countries:||NPM.Germany,|
|NPS Pharmaceuticals Inc was incorporated in Utah in 1986 and reincorporated in Delaware in 1992. The Company is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara is the Company's recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. 'NPS, 'NPS Pharmaceuticals', 'GATTEX', and 'PREOS' are the Company's trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.|
|Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015|
|Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015|
|Weekly CFO Sells Highlight: WRES, NPSP, MKTO, GRPN, RXN Sep 29 2013|
|Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013|
|NPS Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2009|
|George Soros Buys Partner Communications Co. Ltd, CR Bard Inc., Valley Forge Scientific Corp., Sells Aug 15 2006|